Donanemab, made by US pharmaceutical giant Eli Lilly, has made global headlines after crucial phase 3 trial results suggested it slowed cognitive decline in Alzheimer's by 36 per cent.

Source: https://www.dailymail.co.uk/health/article-12045861/NHS-not-ready-dish-breakthrough-Alzheimers-drug-experts-warn.html?ns_mchannel=rss&ns_campaign=1490&ito=1490

Donanemab, on the other hand, is administered once a month and is stopped once patients reach a certain threshold for amyloid levels.

Source: https://indianexpress.com/article/explained/explained-health/the-new-alzheimers-drug-donanemab-8612596/

It's easy to be skeptical, especially on Donanemab, but my bearish sentiment is beginning to change - Lilly could be set for a momentous decade and its share price another 15% upside at least in 2023.

Source: https://seekingalpha.com/article/4569436-eli-lilly-bears-making-huge-mistake?source=feed_all_articles